Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce G Pollock

Showing results (71-80 of 327) with videos related to

Pageof 33
Sort By:
Alcohol, Clinical & Experimental Research|August 7, 2025
Profiles of impulsivity and alcohol use: Unveiling personality, cognitive traits, and DSM diagnosesChloe Lau, Danielle Downie, R Michael Bagby, et al.
Neuropsychiatric Disease and Treatment|May 10, 2011
Performance of Cpred/Cobs concentration ratios as a metric reflecting adherence to antidepressant drug therapyYan Feng, Marc R Gastonguay, Bruce G Pollock, et al.
Journal of Pharmacokinetics and Pharmacodynamics|March 28, 2006
A genetic algorithm-based, hybrid machine learning approach to model selectionRobert R Bies, Matthew F Muldoon, Bruce G Pollock, et al.
The Journal of Clinical Psychiatry|October 28, 2016
Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled TrialHitoshi Sakurai, Takefumi Suzuki, Robert R Bies, et al.
Journal of Psychopharmacology (Oxford, England)|September 16, 2022
Cell-based serum anticholinergic activity assay and working memory in cognitively healthy older adults before and after scopolamine: An exploratory studySusmita Chandramouleeshwaran, Zaid Ghazala, José N Nobrega, et al.
Psychopharmacology|September 15, 2004
Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influencesFrancis E Lotrich, Robert Bies, Matthew F Muldoon, et al.
Psychopharmacology Bulletin|October 17, 2003
An intent-to-treat method for enhancing analysis of clinical trials with rescue medication: a mixed-model approachPatricia R Houck, Sati Mazumdar, Benoit H Mulsant, et al.
British Journal of Clinical Pharmacology|May 4, 2006
Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration samplingYan Feng, Bruce G Pollock, Robert E Ferrell, et al.
Schizophrenia Research|December 3, 2014
Impaired insight into illness and cognitive insight in schizophrenia spectrum disorders: resting state functional connectivityPhilip Gerretsen, Mahesh Menon, David C Mamo, et al.
CNS Spectrums|February 24, 2004
Treatment considerations for anxiety in the elderlyEric J Lenze, Bruce G Pollock, M Katherine Shear, et al.
Pageof 33

Showing results (71-80 of 327) with videos related to

Sort By:
Pageof 33
Alcohol, Clinical & Experimental Research|August 7, 2025
Profiles of impulsivity and alcohol use: Unveiling personality, cognitive traits, and DSM diagnosesChloe Lau, Danielle Downie, R Michael Bagby, et al.
Neuropsychiatric Disease and Treatment|May 10, 2011
Performance of Cpred/Cobs concentration ratios as a metric reflecting adherence to antidepressant drug therapyYan Feng, Marc R Gastonguay, Bruce G Pollock, et al.
Journal of Pharmacokinetics and Pharmacodynamics|March 28, 2006
A genetic algorithm-based, hybrid machine learning approach to model selectionRobert R Bies, Matthew F Muldoon, Bruce G Pollock, et al.
The Journal of Clinical Psychiatry|October 28, 2016
Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled TrialHitoshi Sakurai, Takefumi Suzuki, Robert R Bies, et al.
Journal of Psychopharmacology (Oxford, England)|September 16, 2022
Cell-based serum anticholinergic activity assay and working memory in cognitively healthy older adults before and after scopolamine: An exploratory studySusmita Chandramouleeshwaran, Zaid Ghazala, José N Nobrega, et al.
Psychopharmacology|September 15, 2004
Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influencesFrancis E Lotrich, Robert Bies, Matthew F Muldoon, et al.
Psychopharmacology Bulletin|October 17, 2003
An intent-to-treat method for enhancing analysis of clinical trials with rescue medication: a mixed-model approachPatricia R Houck, Sati Mazumdar, Benoit H Mulsant, et al.
British Journal of Clinical Pharmacology|May 4, 2006
Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration samplingYan Feng, Bruce G Pollock, Robert E Ferrell, et al.
Schizophrenia Research|December 3, 2014
Impaired insight into illness and cognitive insight in schizophrenia spectrum disorders: resting state functional connectivityPhilip Gerretsen, Mahesh Menon, David C Mamo, et al.
CNS Spectrums|February 24, 2004
Treatment considerations for anxiety in the elderlyEric J Lenze, Bruce G Pollock, M Katherine Shear, et al.
Pageof 33